Clinical Trial Update: Study of CART Cell (MB-CART19.1) in Patients With Relapsed or Refractory CD19 Positive NHL [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating MB-CART19.1, a CD19-directed CAR-T cell therapy, in relapsed or refractory CD19-positive non-Hodgkin lymphoma; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• MB-CART19.1

Snippet

Sponsor: King Hussein Cancer Center | Conditions: Non-Hodgkin Lymphoma Refractory/ Relapsed | Phase 2 | Status: RECRUITING